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Angiotensin II type 1 gene reseptor A 1166C polimorfisme; kajian terhadap 
kesanya ke atas keteganan salur darah besar dan tindak balasnya 
terhadap terapi antihypertensi di kalangan populasi Melay-u yang 
manghadapi darah tinggi 
ABSTRAK 
Hipertensi merupakan penyumbang utama kepada penyakit kardiovaskular 
yang merupakan penyebab utama kematian di Malaysia. Ketegangan pembuluh 
darah bes~r merupakan penanda kepada kecacatan dan kematian 
kardiovaskular di kalangan pesakit-pasakit ini. Polimorfisme gen reseptor 
Angiotensin II jenis I, A1166C telah dibuktikan mempunyai kaitan dengan 
"essential hypertension" dan ketegangan pembuluh darah besar yang diukur 
sebagai kelajuan gelombang nadi (PWV). Rawatan menggunakan perindopril 
iaitu enzim perencat penukaran Angiotensin (ACEI) didapati dapat menurunkan 
. PWV di kalangan penghidap hipertensi yang membawa aiel C1166 . Data yang 
menunjukkan kaitan di antara aiel A1166C bagi gen AT1R dengan hipertensi di 
kalangan penduduk Asia adalah bercanggah, hanya sedikit sahaja yang 
diketahui tentang kaitannya dengan P'[VV dan pengaruhnya ke atas tindakbalas 
perawatan anti-hipertensi. Kajian ini dilakukan untuk menentukan (1) hubungan 
di antara polimorfisme C1166 gen AT1 R dengan hipertensi dan PWV di kalangan 
subjek Melayu yang normal serta yang menghidap hipertensi dan (2) untuk 
mengkaji pengaruhnya ke atas PWV dengan membandingkan penggunaan dua 
penghalang sistem renin-angiotensin-aldosteron. 
Kajian secara keratan rentas dilakukan ke atas seramai dua ratus satu orang 
subjek yang menghidap hipertensi tanpa sebarang komplikasi kardiovaskular 
dan juga dua ratus satu orang subjek normal yang telah dipadankan mengikut 
umur dan jantina. Tekanan darah (BP), PWV, pengukuran antropometrik (tinggi, 
berat, ukurlilit pinggang dan pinggul) dicatatkan dan nisbah ukurlilit pinggang 
xxiv 
terhadap pinggul dan indeks jisim badan (BMI) dikira. Sampel darah vena 
diambil untuk ujian makmal rutin dan analisa genetik. Polimorfisme. A 1166C 
dikesan melalui tindakbalas rantaian polimerase diikuti dengan pemotongan 
oleh endonuklease penyekat (restriction endonuclease). Sahagian kedua kajian 
ini melibatkan seramai 46 orang subjek hipertensi tanpa polimorfisme C11 66 bagi 
gen AT1 R dan tanpa sebarang kerosakkan ke atas organ sasaran, telah 
ditentukan sacara rawak untuk menerima samaada perindopril atau losartan 
dengan kajian selari rabun dua belah selama empat bulan dan selepas tempoh 
"washout" selama dua minggu. Sepanjang tempoh kajian dilakukan, sukatan 
ubat yang diberikan telah disesuaikan untuk mancapai tekanan darah yang 
telah ditetapkan (<140/90mmHg) dan sekiranya perlu indapamide 1.5mg akan 
diberikan bersama dengan ubatan kajian. Kadar denyutan jantung, tekanan 
darah sistolik dan diastolic (SBP dan DBP) serta PWV diukur di tahap awal, 
selepas tempoh sebulan dan empat bulan kajian. Dalam kedua-dua kajian , 
PWV diukur menggunakan mesin Complier®. Data daripada kedua-dua kajian 
dianalisa menggunakan program statistik (SPSS 11 .0) yang bersesuaian. 
Keputusan yang diperolehi daripada kajian 1 menunjukkan frekuensi aiel C 11 66 
di kalangan pesakit hipertensi adalah 7.96% dan sebanyak 7.73% di kalangan 
subjek normal oleh itu frekuensi aiel C1166 adalah tinggi sedikit di dalam 
popufasi yang mengh:dap hipe rter:s~ di mana kesignifikan yang d i tujuk~2r; 
adalah pad a tahap sempadan (p=0.091 ). Tiada perbezaan yang signifikan bag i 
SBP dan DBP di antara pembawa aiel C1166 dengan bukan pembawa bagi 
kumpulan hipertensif (p=0.09 dan p=0.161 , masing masing). Begitu juga tiada 
perbezaan signifika bagi SBP dan DBP bagi kumpulan normotensif (p=0.708 
XXV 
dan p=0.838, masing masing) dan di antara populasi kajian keseluruhannya 
bagi SBP dan DBP (p=0.17 4 dan p=0.431, masing masing) . Subjek yan_g 
membawa aiel C1166 menunjukkan bacaan PWV yang tinggi sedikit berbanding 
dengan bukan pembawa di dalam kumpulan hipertensif (11.09 ± 2.08 
berbanding 10.72 ± 1.80; p=0.093) yang mana ia menunjukkan kesignifikan 
pada tahap sempadan. Tiada perbezaan pada PWV di kelangan pembawa dan 
pembawa di antara kumpulan normotensif (9 .86 ± 1.18 berbanding 9.53 ± 1.54; 
p=0.440) . Walau bagaimanapun apabila kedua-dua kumpulan normotensif dan 
hipertensif dianalisa bersama didapati pembawa aiel polimorfisme C11 66 
menunjukkan PWV yang lebih tinggi dan bermakna berbanding dengan yang 
tanpa polimorfisme (1 0.52 ± 1.82 berbanding 10.15 ± 1.80; p=0.040) . Di dalam 
kajian II , sejumlah 19 orang pesakit hipertensi diberikan losartan dan sejumlah 
20 orang pula diberikan perindopril telah berjaya menamatkan kajian. Subjek 
bagi kedua-dua kumpulan dipadankan dari segi umur, pengukuran 
antropometrik dan jantina. Tiada perbezaan yang signifikan dicerap untuk 
tekanan darah yang diukur pada ,tahap awal di antara kedua-dua kumpulan 
(150.89 ± 13.91 I 93.68 ± 10.37 berbanding 151 .85 ± 12.21 I 91 .65 ± 7.54 ; 
p=0.821 dan 0.486) dan bacaan PWV (11.63 ± 1.75 berbanding 10.97 ± 1.69; 
p=0.293) . Selepas empat bulan rawatan terdapat penurunan ya!lg signifikan 
berbanding tahap awal pada SBP (13.57 ± 15.97 ; p=0.002), DBP (8.26 ± 8.54; 
p=0.001) dan bac3an PVVV (0.83 ± 1.19; p=0.007) bagi kumpulan yang 
mengambil losartan dan; SBP (17.95 ± 12.26; p<0.001 ), DBP (9 .25 ± 6.23; 
p<0.001) dan PWV (0.57 ± 1.22; p=0.047) bagi kumpulan yang mengambil 
perindopril. Walau bagaimanapun, tiada perbezaan yang signifikan dicerap bagi 
penurunan tekanan darah sistolik (p=0.342) dan diastolik (p=0.681) serta 
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bacaan PWV (p=0.521) di antara kedua-dua kumpulan di kalangan subjek 
Melayu tanpa polimorfisme C1166 yang menghidap hipertensi. Analisis regresi 
menunjukkan bahawa penurunan di dalam bacaan PWV di antara kumpulan 
yang mengambil losartan dan perindopril adalah tidak bersandaran dengan 
penurunan tekanan darah disebabkan oleh pengambilan ubat-ubat ini (p<0.05) 
dan penurunan tekanan darah hanya menyumbang sebanyak 22% (~=0 . 221) 
bagi kumpulan yang mengambil losartan dan 21% (~=0 . 209) bagi kumpulan 
yang mengambil perindopril, daripada jumlah perbezaan keseluruhan di dalam 
PWV. 
Hasil kerja kajian ini menunjukkan bahawa frekuensi polimorfisme C11 66 adalah 
hampir sama di antara subjek Melayu yang menghidap hipertensi dan yang 
normal dan ianya tidak berkaitan dengan kejadian hipertensi itu sendiri . 
Polimorfisme A 1166C didapati tidak berkait dengan PWV di kalangan pesakit 
hipertensi dan subjek normal tetapi menunjukkan perkaitan yang signifikan 
dengan PWV di kalangan populasi ·Melayu keseluruhannya . Di kalangan subjek 
Melayu yang menghidap hipertensi tetapi tidak membawa polimorfisme ini , 
rawatan menggunakan losartan dan perindopril selama empat bulan 
menunjukkan penurunan yang signifikan dan hampir sama dari segi bacaan BP 
dan PWV. Penurunan bacaan PWV oleh losartan dan perindopril adalah separa 
bersandaran dengan kesarmyct ke atas penurunan tekanan darah. 
Kata kunci : Hipertensi , ketegangan pembuluh darah besar, reseptor gen 
angiotensin II jenis 1, kelajuan gelombang denyutan nadi , Melayu, ubatan anti-
hipertensi . 
xxvii 
Angiotensin II type 1 receptor gene A 1166C polymorphism in hypertension; 
a study on its influence on aortic stiffness and response to 
antihypertensive therapy among Malays 
ABSTRACT 
Hypertension is a major contributor to cardiovascular disease (CVD) which is 
the leading cause of death in Malaysia. Aortic stiffness (AS) is an independent 
marker of cardiovascular (CV) morbidity and mortality in these patients. 
Angiotensin II type 1 receptor (AT1 R) gene A 1166C polymorphism has been 
shown to be associated both with essential hypertension and AS measured as 
pulse wave velocity (PWV). Treatment with angiotensin converting enzyme 
inhibitor (ACEI) perindopril has been shown to reduce PWV among 
hypertensive patients carrying C 1166 allele. Data on association of AT1 R gene 
A1166C allele with hypertension among Asians is controversial, while little is 
known about its association with PWV and its influence on response to 
antihypertensive treatment. Studies in this thesis were done to determine (1) the 
association between C1166 polymorphism of AT1 R gene with hypertension and 
PWV among Malay hypertensive and normotensive subjects and (2) to study its 
influence on reduction in PWV comparing two blockers of the renin angiotensin 
aldosterone system. 
Two hundred and one hypertensive without evidence of CV complication and 
201 age and sex matched normotensive subjects were studied in a cross 
sectional design. Blood pressure (BP) , PWV, anthropometric measurements 
(height, weight, hip and waist circumference) , were recorded and waist hip ratio 
and body mass index (BMI) were calculated . Venous blood samples were 
obtained for routine laboratory investigations and genetic analysis . A 11 66C 
polymorphism was detected by polymerase chain reaction followed by 
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restriction endonuclease digestion. In a second study 46 hypertensive subjects 
without C11 66 polymorphism of AT1 R gene and without evidence of target organ 
damage, were randomly assigned to receive either perindopril or losartan in a 
double blind parallel fashion for 4 months after a washout period of two weeks . 
During the study, dose was adjusted to achieve target blood pressure (<140/90 
mmHg) and if required indapamide 1.5 mg was added to the study medication. 
Heart rate , systolic and diastolic blood pressure (SBP and DBP) and PWV were 
measured at the baseline, one month and 4 months after treatment. In both 
studies PWV was measured using automated Complier® machine. Data from 
both studies was analyzed using statistical software (SPSS 11.0) using 
appropriate tests·. 
Results from study I showed that C1166 allele frequency was 7.96% among 
hypertensive patients and 7.73% among the normotensive subjects . There was 
therefore a slightly higher C1166 allele frequency in the hypertensive population 
which was of borderline significance (p = 0.091 ). There was no significant 
difference in SBP and DBP between carriers and non carriers of C11 66 allele in 
hypertensive group (p=0.09 and p=0.161, respectively) . Likewise there was not 
significant difference in SBP and DBP in the normotensive group (p=O. 708 and 
p=0.838, respectively) and in the overall study population (p=0.17 4 and 
p=0.431, for SBP and DBP respectively). Subjects carrying C: 1166 allele had 
slightly higher PWV as compared to non carriers in the hypertensive group 
(1 1.09 ± 2.08 vs. 10.72 ± 1.80; p = 0.093) which was also of borderline 
significance. No difference in PWV was seen among carriers and non carriers in 
the normotensive group (9.86 ± 1.18 vs . 9.53 ± 1.54, p = 0.440) . However 
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when both normotensives and hypertensives were analyzed together, C 1166 
polymorphism carriers had significantly higher PWV as compared to those 
without this polymorphism (10.52±1 .82 vs. 10.15±1 .80, p= 0.040) . In study 11 , a 
total of 19 hypertensive patients on losartan and 20 on perindopril completed 
the study. In both the groups patients had similar age, anthropometric 
measurements and sex distribution. There was no significant difference in 
baseline BP (150.89 ± 13.91/93.68 ± 10.37 vs. 151 .85 ± 12.21/91 .65 ± 7.54, p 
= 0.821 and 0.486) and PWV (11 .63 ± 1.75 vs.10.97 ± 1.69, p =0.293) between 
the groups. After 4 months treatment there was a significant reduction from 
baseline in SBP (13.57 ± 15.97, p = 0.002), DBP (8.26 ± 8.54, p = 0.001) and 
PWV (0.83 ± 1.19, p=0.007) in the losartan group and SBP (17.95 ± 12.26, p 
<0.001 ), DBP (9.25 ± 6.23, p <0.001) and PWV (0.57 ± 1.22, p = 0.047) in the 
perindopril group. However there was no significant difference in reduction in 
SBP (p=0.342), DBP (p = 0.681) and PWV (p = 0.521) between the two groups 
among Malay hypertensive subjects without C1166 polymorphism. Regression 
analysis showed that reduction in RWV by losartan and perindopril group was 
independent of reduction in BP by these drugs and reduction in BP explained 
about 22 % (~ = 0.221) in losartan group and 21% (~ = 0.209) in perindopril 
groups, of the total change in PWV. 
among Malay hypertensive and normotensive subjects and it is not associated 
with hypertension. A 1166C polymorphism is not associated with PWV in 
hypertensive patients and normotensive subjects but is significantly associated 
with PWV in the overall Malay population. Among Malay hypertensive subjects 
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CHAPTER 1 
INTRODUCTION 
1.1 Hypertension, cardiovascular disease and its impact 
Cardiovascular disease (CVD) is the leading cause of death worldwide. 
According to 2003 report by the world health organization (WHO, 2003) most 
deaths in today's world are due to non-communicable diseases (33.2 million) 
and over half of these (16.7 million) are the result of CVD. WHO has therefore 
called CVD "a neglected global epidemic" and has highlighted the growing 
severity of this problem (WHO, 2003) . In the past CVD has been considered a 
disease of civilization and high socioeconomic status as it was associated with 
modern life style and dietary habits. Today CVD is seen with alarmingly 
increasing prevalence in the developing countries as well (Forrester et at., 
1998). In these countries where infectious disease was the main cause of 
death, a rapid increase in CVD related mortality and morbidity has become an 
obstacle to both social and economic development. The burden of deaths and 
disability in developing world caused by cardiovascular conditions now 
outweighs that imposed by long standing communicable diseases (WHO, 
2003). In fact CVD causes twice a& many deaths in developing countries as in 
developed countries where it is now on the decline largely due to better and 
improved primary prevention and treatment. 
According to the world health report in 2001, the number of deaths in South 
.As ian region due to CVO was 5829 wh!ch was the highest in the 'Nor!d at that 
time (WHO, 2001 ). This figure has increased to 6078 deaths per year according 
to 2003 world health report (WHO, 2003). To aggravate the problem there is a 
relatively earlier ons.et of the disease among Asian people as compared to the 
western world (Singh et a/., 2000) . In Malaysia CVD is the principal cause of 
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morbidity and mortality and constitutes a significant burden on the national 
resources . In 1992 alone it caused 30% of the total 40% deaths medically 
recordod in the country. The majority were due to ischemic heart disease (IHD) . 
According to 1995 health survey it was the fourth cause of hospitalization 
ranking only after pregnancy, labour and accidents but still the top cause of 
mortality in the country (Malaysia, 1995). In 1997 and 1998, CVD maintained 
the same rank but the number of deaths increased from 3497 in 1995 to a total 
of 4,248 deaths. In 1999 a more comprehensive review of the statistics revealed 
that the death rate reported only in government hospitals due to CVD was 26.5 
per 100,000 in 1990, 23.59 in 1997, 23.12 in 1999 & 22.88 in 2000. Death rate 
due to hypertension or hypertension related heart disease was 8.8 per 100,000 
in 1990, 8.86 in 1997, 8.71 in 1999 and 7.85 in 2000 (Malaysia, 1999, Malaysia, 
2001, Malaysia, 2002). These figures did not include the deaths occurring 
unreported as well as those in the private hospitals. 
A large portion of CVD related morbidity and mortality is a result of vascular 
complications of hypertension. Hypertension or pathological rise in BP is a 
major determinant and risk factor for premature deaths due to stroke, coronary 
artery disease (CAD), cardiac and renal failure . In 1978 WHO reported that 
hypertension is the most common of CVD and reported that presence of" high 
BP is clearly associaterl with !;horter life expectancy (WHO Geneva . 197A) The 
positive relationship between BP and CV disease has long been recognized. 
This relationship is strong , continuous , independent, predictive and etiologically 
significant for those. with or without CAD (Flack et a/., 1995, Stamler et a/., 
1991 ). In 2003, WHO reported a list of risk factors indicative of individual's 
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future health status and the foremost among the top 10 risk factors worldwide is 
raised -BP or hypertension. Other risk factors related to life style follow 
hypertension such as alcohol intake and tobacco use, cholesterol and obesity. 
All these factors contribute to and interact with high BP to cause CVD disease. 
Hypertension and its complications such as cerebrovascular disease and 
hypertensive heart disease are the principal cause of death in Malaysia 
according to the Second National Health and Morbidity Survey (NHMS2) done 
in 1996 (Lim eta/. , 2004). 
According to the estimates in NHMS2 the overall prevalence of hypertension 
among adults aged 30 years and above was 33% "(Lim eta/. , 2004). A higher 
prevalence of hypertension in older age group and in women has been 
reported . Out of the total, the majority remained undiagnosed. Only 33% were 
aware of their hypertension and 23% were currently on treatment. Among those 
receiving treatment only 6% achieved an optimal control of BP. There was no 
difference in the mean BP between treated and untreated hypertensive patients 
(Lim eta!., 2004). The prevalence of hypertension has increased from 14.4% in 
the first national health and morbidity survey (1986 unpublished data) and in 
earlier small surveys (Kandiah et at., 1980) to 33% reported by NHMS2. The 
prevalence rates found are among the highest reported in the literature 
le'v'ealing a grave situation. Hypertension and its sequel among Malays was 
also earlier highlighted by studies done in Singapore (Hughes, 1989). 
In NHMS2 (Lim et a/., 2004), different geographical regions in Malaysia 
presented differences in prevalence of the disease, complications, undiagnosed 
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cases and inadequacies of the treatment. In Kelantan, a higher prevalence of 
isolated systolic hypertension (iSH) (3.2%) and possible undiagnosed cases of 
hypertension (19.5%) was recorded . Significantly lower proportions of 
diagnosed patients were on treatment and the highest number (55. 7%) of those 
stopping the antihypertensive treatment in Malaysia was also reported in 
Kelantan. According to the report, out of the three main ethnic groups in 
Malaysia, highest prevalence was seen among the Malays which were in 
agreement with higher figures for Kelantan, a state predominantly inhabited by 
Malays. 
Clearly such a grave situation calls for increased awareness and 
implementation of preventive measures as well as adequate treatment in the 
community. However an efficient prevention and adequate treatment requires 
complete knowledge of pathogenesis of disease and its complications , right 
from the cellular and molecular level which is influenced by cultural and genetic 
factors. The established role of culttJral, environmental and genetic factors in 
aetiology, pathogenesis, and long term prognosis of hypertension positively 
recommended a study of these factors in different populations and therefore 
among Malays. 
1.2 Defini i.iun of hypertension 
Hypertension may be defined as "a state of abnormal arterial structure and 
function associated with endothelial dysfunction, vascular smooth muscle 
constriction or remodelling , increased impedance to left ventricular ejection and 
propensity for atherosclerosis often and not always manifested by an elevated 
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BP" (Cohn, 1998). In clinical practice hypertension is defined as a BP level 
equal to. or greater than 140/90 mmHg systolic and diastolic (Sixth report of the 
Joint National Committee; JNC VI, on prevention, detection, evaluation and 
treatment of blood pressure, 1997) Malaysian clinical practice guidelines: CPG, 
2002 (Zaher et at., 2002). Hypertensive patients may then be classified 
according to JNC VI BP classification (1997) (table 1.1 ). 
1.3 Aetiology of hypertension 
A pathological increase in BP or hypertension can occur as a result of pathology 
in other organ systems of the body (secondary hypertension) or in the absence 
of a known cause (primary or essential hypertension). Secondary hypertension 
only comprises a small portion of all known hypertension cases (5%) while in 
the majority (95%) a definite cause of hypertension is unknown. Table (1 .2) 
shows a list of causes of secondary hypertension. Essential hypertension on the 
other hand is a form of hypertension that cannot be attributed to the existence 
of another problem or disease. Essential hypertension is known to run in 
families which suggests a role of inheritance in its aetiology. 
The influence of inheritance on hypertension and the role of interaction between 
multiple genes and environment has been proposed (Cruz-Coke, 1981 ). It has 
been considered a genetic disease which occurs because of environmentr~l 
impact (Mendlowitz, 1982). Therefore interindividual differences in BP are 
explained based on differences between the genetic structures of an individual 
as opposed to genetic structure of the population. Different individuals may 
possess different genetic defects in a population (Lifton, 1995). In order for 
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Table1.1 
Classification of BP for adults aged 18 years and older 
- - -
JNC VI (1997) 
Blood pressure mmHg 
Category Systolic Diastolic 
Optimal <120 And <80 
Normal <130 And <85 
High normal 130-139 Or 85-89 
Hypertension 
Stage 1 140-159 Or 90-99 
Stage 2 160-179 Or 100-109 
Stage 3 ~ 180 Or ~ 110 
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Table 1.2 
Type~_ and Gausas_ of secondary hypertension 
(Adapted from Kaplan, 2002) 
Systolic and diastolic hypertension Foods containing tyramine and mono 
amine oxidase inhibitors 
Renal 
Renal parenchymal disease 
Acute glomerulonephritis 
Chronic glomerulonephritis 
Chronic nephritis 
Polycystic disease 
Diabetic nephropathy 
Hydronephrosis 
Renovascular hypertension 
Renal artery stenosis 
Other causes of renal ischemia 
Renin producing tumours 
Renoprival 
Primary sodium retention (Liddle's 
syndrome, Gordon's syndrome) 
Endocrine. 
Acromegaly 
Hypothyroidism 
Hyperthyroidism 
Hypercalcemia 
(hyperparathyroidism) 
Adrenal disorders 
Cortical disorders 
Cushing's syndrome 
Primary aldosteronism 
Congenital adrenal hyperplasia 
Medullary tumours 
(pheochromocytoma) 
Extra adrenal chromaffin tumors 
11-(3-hydroxysteroid 
deficiency/inhibition 
Carcinoids 
Exogenous hormones 
Estrogens 
Glucocorticoids 
Mineralocorticoids 
Sympathomimetics 
Erythropoietin 
Coarctation of aorta 
Pregnancy induced 
Neurologic disorders 
Increased intracranial pressure 
Sleep apnoea 
Quadriplegia 
Acute porphyria 
Familial autonomia 
Lead poisoning 
Guillain Barre' syndrome 
Acute stress (including surgery) 
Psychogenic hyperventilation 
Hypoglycemia 
Burns 
Alcohol withdrawal 
Sickle cell crisis 
After resuscitation 
Perioperative 
Increased intravascular volume 
Alcohol 
Nicotine 
Cyclosporine, tacro!imus 
Systolic hypertension 
Increased cardiac output 
Aortic valvular insufficiency 
Atriovenous fistula , patent ductus 
Thyrotoxicosis 
Paget's disease of the bone 
Beriberi 
Arteria! rigidity 
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possess different genetic defects in a population (Lifton, 1995). In order for 
hypertension to be manifest; a single or -a number of genetic defects may be 
present. 
Although common, the aetiology and mechanism of essential hypertension is 
not fully understood (Meredith et at. , 2003). Current therapeutic strategy for the 
disease is only empirical as a result of which may be one reason why a large 
number of the patients never achieve an optimal response. This not only 
increases the cost of treatment, incidence of side effects but also leads to a 
poor patient compliance finally leading to complications of hypertension. This 
phenomenon is very well documented among Malaysian hypertensive patients 
as was shown in the NHMS2 stated earlier in this chapter. This scenario is also 
a consequence of the fact that it is a complex disease in which a multitude of 
genetic factors, environmental stimuli , physiological systems and biochemical 
processes interact to influence arterial function , the BP level and therefore a 
susceptibility to develop hypertension. 
Hypertension is associated with abnormal arterial and endothelial function 
which affects both large and small arteries . In this regard stiffness of large 
arteries such as aorta and its major branches is particularly relevant as it 
directly affects he<:11 t UJJslr earn . L.arge artery stiffness causes increased lett 
ventricular load and reduced coronary perfusion besides influencing target 
organs like brain and kidney down stream. Most of the complications of 
hypertension are associated with arterial stiffness. Reduction in BP in response 
to antihypertensive drug therapy may or may not be related with an 
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improvement in arterial function. As a result different drugs cause reduction in 
BP with or without reduction in CV risk associated with hypertension. It is 
therefore of interest to understand the basis of hypertension, its essential 
accompaniment arterial stiffness as well as the influence of drug therapy. 
1.4 Structure and function of large arteries 
Human arterial system is a complex network of tubes which serves to deliver 
blood pumped from the heart through smaller arteries and arterioles into organs 
and tissues of the body. In doing so it has to function as a conduit, transmitting 
blood to the tissues as well as a cushion smoothing out pulsations caused by 
intermittent cardiac contractions so as to achieve a steady blood flow to the 
tissues. This cushioning function depends upon the mechanical properties of 
the arteries which are determined by the structural components of the arterial 
wall. Among the three layers of arterial wall i.e . the intima, media and adventitia , 
tunica media or the intermediate layer is most important in determinin~ the 
cushion or elastic properties of the -artery. The intima consists of a single layer 
of endothelial cells, a fenestrated sheet of elastic fibres and the internal elastic 
lamina . Though it does not contribute to the mechanical behaviour of the arterial 
wall , it is a rich source of substances and signal transduction mechanisms 
which influence the mechanical function of the arteria l wall (Van Bartel et at. , 
'1 nn "' \ 
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Tunica media, the main determinant of mechanical properties, is composed of 
smooth muscle fibres , a connecting molecular grid composed of 
mucopolysaccharides and variable amount of collagen and abundant elastic 
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tissue especially in aorta . Vascular smooth muscle cells (VSMC) are known to 
be of many different types based on their characteristics such as contractile , 
proliferative, and synthetic or apoptotic (Schwartz and Mecham, 1995). The 
relative proportion of each of these phenotypes depends upon age, location in 
vascular tree and the prevailing pathological condition (Van Bartel et a/., 2001) 
like hypertension. Contribution of each of these types, to the overall mechanical 
behaviour of the arterial wall is however not yet known. The outermost layer 
adventitia is mainly composed of fibroolasts and collagen and is abundant in 
central arteries such as the aorta . It is a major determinant of stiffness of large 
arteries and may be modified through breakdown, cross linking and glycation. 
These important components of the arterial wall, although present in all the 
arteries, exhibit differences in their content between central and peripheral 
arteries which make them elastic or muscular in character. Therefore on the 
basis of wall structure arteries can be divided into three types ; large elastic 
(conduits) arteries e.g. aorta and its major branches, medium and small sized 
arteries e.g . radial and its branches and resistance arteries e.g. arterioles or the 
distributing arteries. 
Large elastic arteries such as aorta and its main branches carotid , 
brachiocephalic and pulmonary arteries have characteristically thick tunica 
med!a r!ch in concentr!ca!!y arranged !nmina of clastic fibres. \.'V;thi n this elastic 
lamina are smooth muscles, reticular fibres and chondroitin sulphate ground 
substance. On the other hand the tunica media of the medium sized peripheral 
arteries is predominantly composed of smooth muscles with some elastic and 
reticular fibres Those of arterioles consist of a few layers of smooth muscles 
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intermixed with collagenous and reticular fibres. It is therefore the elastic 
lamellae and their ratio with the collagen content of-tunica media- of the aorta , 
• 
which is responsible for its elastic nature and determines its buffering or cushion 
function . The elastic fibres are responsible for normal arterial distensibility and 
compliance. During systole, it stores the blood pumped by left ventricle which is 
then delivered to the body during diastole in a continuous stream. 
1.5 Arterial function and blood pressure regulation 
As a result of the conduit and cushioning functions of arteries, arterial blood 
pressure has two components, a steady component represented by the mean 
blood pressure and, a pulsatile component represented by pulse pressure. 
Mean blood pressure is determined by cardiac output and total peripheral 
resistance which is in turn determined by the calibre and number of small 
arteries and arterioles . Pulse pressure on the other hand represents oscillations 
around the mean pressure, the systole and diastole being the highs and lows of 
the oscillations. Magnitude of pulse pressure depends on the pattern of left 
ventricular ejection, the viscoelastic and propagative properties of large arteries 
and the timing of reflected waves (Safar, 1996). A rise in peripheral resistance 
causes a proportionate rise in systolic and diastolic pressure therefore mean 
arterial pressure . On the other hand a reduction in viscoelasticity i.e. increase in 
systolic and diastolic pressure rising and decreasing respectively , without 
causing a change in the mean arterial pressure but widening the pulse pressure 
(Safa r, 1996) (fig . 1.1 ). 
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(a) (b) (c) 
Figure 1.1 
Blood pressure curves in compliant vs. stiff arteries 
Effect of increased resistance and reduced elastance on blood pressure curve, 
peak systolic and end diastolic pressure . 
a) Distensible artery with normal resistance and normal BP curve 
b) Distensible artery with increq_sed resistance and BP curve showing a 
proportionate increase in systolic and diastolic BP. 
c) Stiff artery with increased resistance, BP curve shows a disproportionate 
rise in systolic BP 
(Adapted from Safar, 1996) 
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Pulse pressure is the difference between systolic and diastolic blood pressure 
(SBP and DBP) . In young healthy subjects , pulse pressure - ~ ncreases 
significantly from central to peripheral arteries , principally because of a rise in 
systolic pressure with a relative fall in diastolic pressure. This is due to 
differences in mechanical properties of central and peripheral arteries as a 
result of different collagen and elastin content in their tunica media. Carotid 
artery pulse pressure which is virtually identical to aortic pressure is lower than 
radial and femoral artery pulse pressure. The highest pressure values are seen 
in the common femoral arteries. This pressure gradient along the arterial tree is 
similar in both normotensive and young hypertensive subjects although 
absolute values are higher in hypertensive patients but diminishes with old age. 
In pulsatile hemodynamic studies , factors influencing pulse pressure may be 
analyzed as the summation of an incident press'ure wave originating from the 
heart and reflected pressure waves returning to the heart from the resistance 
vessels in peripheral circulation i.e. a forward and a backward wave . Forward 
wave is influenced by ventricular ejection and stiffening of aorta , while backward 
reflected wave depends on sti ffening of arteries and the site of reflection points 
i.e. the resistance vessels (Safar, 1996) (fig . 1.2). Arterial wall viscoelasticity is 
a determining factor for speed of wave propagation across the arterial tree and 
the timing of '.":ave ref!ections. !ncreased stiffness of arteries leads to !ncreased 
pulse wave velocity (PI./'N) and reflection sites (i.e. resistance vessels) appear 
to operate closer to the heart producing an earlier reflection of aortic backward 
wave during systole instead of diastole. An earlier reflection of backward wave 
leads to a summation of the fo rward and backward waves during systole , higher 
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Forward and backward waves determining the pulse pressure 
Summation curve resulting from the ettects ot forward and backward waves 
together with decomposition of the summation curve into forward and backward 
waves (top) . 
Factors affecting forward and backward waves determine the pulse pressure 
and the pulse waveform (bottom) 
(Adapted from Safar, 1996) . 
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BP and pronounced systolic peak and systolic pressure (O'Rourke, 1989, Safar 
and Laurent, 1993). An increase in the systolic arterial pressure accelerates the 
fatigue of the arterial wall and arterial damage producing a self perpetuating 
cycle (London and Guerin , 1999). Normally velocity of the pulse wave is low as 
in young healthy subjects and reflection points are principally observed at the 
narrowing of small resistance vessels causing a return of reflection wave during 
diastole. 
With aging there is fragmentation and fracture of the elastic lamella followed by 
fibrous remodelling . Fracture of elastic fibres occurs as a result of repetitive or 
cyclic stress with each cardiac cycle. The aortic media hence becomes 
disorganized with faulty areas of mucoid degeneration or medionecrosis as may 
be seen in elderly or older patients with hypertension (O'Rourke, 1995). As a 
result, with aging and high BP, increased P\NV promotes a disproportionate 
increase in systolic over diastolic pressure. Therefore for the same mean 
arterial pressure, pulse pressure is higher in older subjects than younger ones 
(fig .1.3). For the same reason pulse pressure becomes similar through out the 
arterial system with disappearance of earlier mentioned pulse pressure gradient 
between central and peripheral arteries . Stiffness of central elastic arteries as 
compared to peripheral arteries increases markedly with age. The central 
pressure increases vv·hile the femoral pressure docs not change as a 
consequence of differential increase in stiffness of central over peripheral 
arteries (Benetos et at., 1991 a). Preferential increase in central pressure 
increases the systolic pressure while there is a relative fall in DBP. Therefore 
risk of CAD in middle aged and elderly subjects increases with decreasing DBP 
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Younger Older 
Figure 1.3 
BP curves for younger and older subjects. 
For similar mean blood pressure, pulse pressure the difference between systolic 
and diastolic BP is higher in elderly -
(Adapted from Safar, 1996). 
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i.e. widening of the pulse pressure and large artery stiffness (Franklin , 1999a). 
A wide pulse pressure constitutes a significant pred ictor of CV events such as 
myocardial infarction (MI) and is a strong predictor of CV risk even among 
normotensive subjects (Benetos , 1999). 
1.6 Arterial stiffness as an index of arterial function 
The principal function of large central arteries like the aorta is its buffering or 
cushion function and the best clinical index representative of this is arterial 
compliance. Arterial compl iance is defined as "change in volume for a given 
change in pressure", i.e. 
C = lt!V I !tiP 
where, C is compliance, lt!V is change in volume and !tiP is change in pressure . 
In arteries the pressure volume relationship is curvilinear because of variable 
composition of constituGnts of arterial wall. As a result arterial compliance is 
pressure dependent and varies inversely with level of mean arterial pressure 
within a physiological range . If the artery becomes less distensible, its storage 
capacity diminishes for any given pressure . Under these circumstances either 
large fraction of the stroke volume must run off during systole or a greater rise 
in systolic pressure must occur to accommodate the increased volume in non-
compl iant or stiff arterial tree . Arterial stiffness therefore has an inverse 
reiationship wi th arteriai compiiance, the stiffer the artery the iesse1 its 
compliance. Arterial stiffness can therefore serve as an indicator of large arterial 
function. 
Properties like stiffness and compl iance are dependent upon blood pressure 
(O'Rourke and Mancia, 1999) . The higher the BP, the lesser the arterial 
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compliance and greater will be the stiffness. Both elastic and muscular 
component of arterial wall are essential for the arterial function and its structural 
integrity. At normal or low levels of pressure as in young healthy subjects , the 
load is mainly borne by the elastic fibres which are readily stretchable (Giagov 
et at., 1992). As the pressure and wall stretch increases, the collagen fibres are 
progressively recruited and the artery behaves as though composed of collagen 
alone and becomes stiff (Safar, 1996). 
1.6.1 Pulse wave velocity as a measure of arterial stiffness 
As speed of travel of a wave in any material is determined by the stiffness of 
that material , arterial stiffness can also be defined in terms of PWV. Pulse wave 
velocity is therefore an index of arterial stiffness. Newton was the first to show 
that velocity of wa•Je propagation in a compressible material was determined by 
its stiffness and density. Later this concept was found to be true in case of 
arteries in which blood acts as an incompressible material and the energy 
imparted to the arterial tree with each heart beat travels along the elastic arterial 
wall. The stiffer the material the faster will be the speed of travel of pulse wave . 
Pulse wave velocity , measures velocity of energy imparted to the arterial tree by 
cardiac contractions and is a pure measure of arterial properties (Kelly et a/., 
1996). The speed of propagation of pulse wave along the vessel wall is much 
f3StGr than the Speed ul oiood fiow within ItS lumen. 
Pulse wave velocity is perhaps the best and most widely used technique for 
measurement of sti ffness of aorta and its major branches (lzzo and Shykoff, 
2001 ). Among the non invasive measures to evaluate the structure and function 
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of large arteries, it is most simple and accurate (lzzo and Shykoff, 2001 ). Pulse 
wave velocity has been used to determine the influence of vasoactive agents 
(Rehman et at., 2002, Rehman et at. , 2001) as well as antihypertensive drugs 
(Asmar, 2001 , Benetos eta/., 1996a). Non invasive measurement of PWV using 
machines such as Complior® has become a technique of choice due to its 
simplicity and reproducibility and also because it is atraumatic. This 
measurement technique using the Complier® program has been validated 
(Asmar eta/., 1995a). Carotid femoral PWV indicates stiffness of aorta and has 
been used in a number of clinical studies as a measure of aortic stiffness (Amar 
eta/., 2001, Asmar eta/., 2001a, Blacher eta/. , 1999, Meaume eta/., 2001 , 
Taquet et at., 1993, Yongbin· et at., 2003) . Aortic stiffness (AS) measured as 
carotid femoral (CF) PWV is considered the best indicator of CV risk (lzzo and 
Shykoff, 2001 ) . 
1.6.2 Hypertension and arterial stiffness 
Hypertension is a major determinant" of arterial stiffness second only to aging 
(Asmar, 1999, Asmar, 2001 ). Arterial alterations in hypertension occur long 
before the appearance of any CV symptoms (Shargorodsky et a/., 2002) . 
Clinical studies have shown that stiffness of arteries occurs early 1n 
hypertension at the time when BP is only elevated to a borderline level of 
hypertension (Asrnar, ·j 999, Messerli et at., 1985, Simon et a/. , 1992, Ventura et 
a/., 1984). Increased arterial stiffness has been shown in newly diagnosed and 
untreated hypertensive subjects (Ngim et a/., 1999), middle aged patients with 
sustained hypertension (Simon et a/., 1992) as well as in elderly patients with 
ISH (Messerli et a/., 1982). The age related increase in arterial stiffness is 
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accelerated in hypertensive patients and has been shown to be augmented in 
phases according to the severity of hypertension (Tomiyama et a/., 2004). 
Besides these , normotensive offspring of hypertensive patients have been 
shown to have increased AS (Yasmin eta/., 2004) . 
Increased BP contributes to arterial stiffness in two ways, passive or reversible 
effects and structural or potentially irreversible effects. Passive and reversible 
effects of high BP influence both elastic and muscular arteries and are due to 
passive dilatation of the artery with increased BP. Passive dilatation of arteries 
due to high BP, recruits collagenous fibres to the elastic fibres already bearing 
tension on the arterial wall . As a result artery behaves as though stiff (Nichols 
and O'Rourke , 1990). This passive effect of raised BP is abolished by reduction 
in BP with antihypertensive agents. In addition to the ·stretch effect of raised 
pressure, early changes and abnormalities in the arterial wall structure also 
contribute to arterial stiffness in hypertension (Asmar, 1999). These structural 
characteristics are responsible for large artery stiffness and include smooth 
muscle cell hypertrophy in the medial layer, collagen deposition and dysfunction 
in proteoglycan metabolism (Benetos et a/. , 2002, Et-Taouil et a/., 2003) . Such 
intrinsic alterations in mechanical properties of arteries are observed more at 
the site of central arteries like aorta and its proximal branches than the 
per!pher3! 8:-tclies, and are: rnore pronounced with increasmg age (Van Bartel et 
a/. , 2001 ). These changes contribute to vascular remodelling and hypertrophy in 
hypertension. 
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Vascular remodelling and hypertrophy in hypertension are due to activation of 
vasoactive substances like Ar.g li and endothelial dysfunction . Endothelial 
dysfunction contributing to functional and later structural changes in 
hypertension (Kung and Luscher, 1995) may vary according to the arterial 
territory. Endothelial dysfunction is associated with abnormalities in nitric oxide 
(NO) production and I or release (Van Bartel et at., 2001) and bradykinin-
dependent hyper-reactivity of smooth muscle cells and vasa vasorum . Such 
related mechanisms influence wave reflections and contribute to aortic wall 
stiffness (Et-Taouil et a/., 2003). Improvement in arterial stiffness with 
antihypertensive drugs such as Ang II type 1 receptor blockers (ARB) has been 
suggested to be due to correction of endothelial dysfunction through blockade 
of effects of Ang II (Mahmud and Feely, 2002a) . 
In short hypertension causes major changes in the arterial pulse through large 
artery stiffening , increased PWV and early wave reflection (O'Rourke , 1995). 
There is a close, well known relationship between arterial stiffness and level of 
BP. At any given ventricular ejection, BP level is determined not only by 
peripheral resistance i.e. arteriolar constriction but also by the degree of arterial 
stiffness and resultant changes in amplitude as well as timing of the re flected 
waves. Therefore the greater the aortic stiffness , the higher will be the pulse 
ve!oc!ty with ear!ier return of the l eflecteJ waves during systole mstead of 
diastole. This will lead to a greater augmentation of the systolic pressure (Safar 
and Frohlich , 1995) and as a result a wider pulse pressure . Increased systolic 
pressure due to aortic stiffness increases left ventricular afterload and 
hypertrophy with increased myocardial oxygen demand . Increased myocardial 
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oxygen demand coupled with reduced coronary perfusion due to relative fall in 
-
DBP leads to myocardial ischemia. Hence large artery stiffness in hypertension 
has deleterious effects on the heart upstream and target organs such as the 
kidney and the brain downstream by increasing both pulsatile pressure and 
shear stress. Alterations in large artery function in hypertension are therefore 
directly related to the classic complications involving central nervous system, 
heart and kidney and may be observed independent of age and atherosclerotic 
lesions. 
1.6.3 Clinical consequences of arterial stiffness 
Large artery stiffness cause major changes in circulation which manifest as 
systolic hypertension and increased pulse pressure, left ventricular hypertrophy 
and early atherosclerotic damage. These cl inical consequences of large artery 
stiffness are described below. 
1.6.3.1 Systolic hypertension aRd wide pulse pressure 
An increased pulse pressure is the most obvious consequence of aortic 
stiffness . Increased arterial stiffness contributes to systolic hypertension 
(Simon et a/. , 1992) by increasing velocity of the forward pulse waves which 
reach the reflection points in the arterial tree earlier resulting in earlier return 
cf the rcf!ccted vva·.;a during systole. lt has been noticed that sy~luiic BP 
increases with age and the diastolic BP increases until 50 years of age and 
then declines (Safar, 1996). This disproportionate reduction in DBP is mainly 
due to shift of the reflected pulse w3ves in systole from diastole as a result 
of arterial stiffness and is associated with widening of the pulse pressure . 
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Systolic hypertension occurring consequent to arterial stiffness then 
interacts with- age to further promote arterial stiffness (lzzo and Shykoff, 
. 2001) setting up a self perpetuating cycle. 
1.6.3.2 Left ventricular hypertrophy 
Left ventricular hypertrophy (LVH) occurs secondary to chronic increase in 
left ventricular afterload. Cardiac work load is determined by the heart rate, 
cardiac contractility as well as by systemic vascular resistance and aortic 
stiffness. Aortic stiffness increases cardiac load not only by generating larger 
initial systolic pressures but also by an earlier return of the reflected waves . 
Initially LVH was thought to be the consequence of chronic elevation of BP. 
However observation of LVH among subjects with normal BP showed that 
measurement of SBP at the brachial artery misinterprets the central systolic 
pressure and cardiac afterload, by not taking the effect of reflected waves 
into account (lzzo and Shykoff, 2001, Simon et al .. 1992). On the other 
hand, strong correlation of measures such as PWV with LVH (Bouthier et at., 
1985, Girerd et al .. 1991) suggest that arterial stiffness contributes to LVH 
by an increase in systolic as well as pulse pressures , important determinants 
of cardiac work load . Both systolic hypertension, with wide pulse pressure 
and arterial stiffness have been shown to be important CV risk factors 
(Safar, 200i). 
1.6.3.3 Atherosclerosis 
In the presence of atherogenic risk factors such as smoking and high 
cholesterol level , increased large artery stiffness may lead to early 
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